Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Background: Antipsychotic medications are the mainstay of treatment for schizophrenia and are associated with a reduction in psychiatric hospitalization and overall mortality. Some evidence suggest that antipsychotic medications might have a varying effect on the improvement of comorbid substance use disorders (SUDs), with clozapine showing more favorable outcomes. Aim: We systematically reviewed all available evidence on effects of clozapine on the improvement of SUDs other than nicotine. Methods: Electronic searches of MEDLINE, Embase, PsycINFO, and CINHAL were conducted up to March 1, 2022. Studies of any methodological design involving two concepts: (1) clozapine and (2) SUD terms (excluding nicotine) were included. For SUD outcomes with three or more comparative studies with available raw data meta-analysis was performed. SUD outcomes not meeting criteria for meta-analysis were described qualitatively. Risk of bias was examined using “Downs and Black,” and “Q-Coh” instruments. Results: The majority of individuals in the included 31 studies were male and of European ancestry. Abstinence was the most common outcome. Most of the studies were of low-to-moderate quality, and none of the studies met all the quality criteria. Pooled findings from four observational studies in samples of patients with predominantly comorbid alcohol use disorder showed that clozapine treatment is associated with significantly higher odds of remaining abstinent. In addition clozapine was associated with decreased odds of psychiatric hospitalization in all but one observational study. Conclusions: Our systematic review and meta-analysis builds upon previous reviews, and it suggests the association of clozapine treatment with significantly higher odds of remaining abstinent from substance use and decreased likelihood of psychiatric hospitalization, compared with continuing treatment with other antipsychotic medications. Still, the validity of this association needs greater exploration and providing recommendations for the utility of clozapine in individuals without treatment-resistant psychosis and comorbid SUDs would be premature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pharmacological interventions, including medications such as clozapine, have shown promise in treating individuals with comorbid SUDs and psychiatric conditions, with research suggesting higher odds of abstinence and reduced psychiatric hospitalization”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, the effectiveness of such treatments remains inconclusive due to limited sample sizes and insufficient reporting in randomized controlled trials”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [30]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Downs, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252 · cited 1×
“We used Downs and Black instrument (Downs and Black, 1998) for RCTs, which contains 27 items for randomized and non-randomized comparative studies, providing a total score of 28 for each study.”
Method(2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00395-3 · Cited by 6,481 · cited 1×
“Four observational studies (Brunette et al., 2006, 2008; Drake et al., 2000; Green et al., 2003) with available raw data reported the proportion of individuals with concurrent SSD and SUDs (predominantly alcohol) who remained abstinent (defined as either complete cessation of use or use without…”
BackgroundPRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement
McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.01.021 · Cited by 5,700 · cited 2×
“Systematic searches of the peerreviewed literature were conducted following PRESS guidelines (McGowan et al., 2015) in consultation with a medical librarian in four electronic databases (i.e., MEDLINE, PsycINFO, Embase, and CINAHL) from inception to March 1, 2022.”
MethodTiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670 · cited 1×
“Antipsychotic medications are the mainstay of treatment for schizophrenia and are associated with a reduction in psychiatric hospitalization (Tiihonen et al., 2017) and overall mortality (Taipale et al., 2018).”
BackgroundHaddaway, N. R., Grainger, M. J., & Gray, C. T. (2022) · Research Synthesis Methods · doi:10.1002/jrsm.1563 · Cited by 604 · cited 1×
“In addition, a web-based citation chaser (Haddaway et al., 2022) was used for backward and forward citation chasing for additional references not identified in our primary searches.”
MethodHunt, G. E., Large, M. M., Cleary, M., Lai, H. M. X., & Saunders, J. B. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.07.011 · Cited by 482 · cited 3×
“441), with trends for increased substance use over time (Hunt et al., 2018).”
BackgroundInfluentialAshok, A. H., Mizuno, Y., Volkow, N. D., & Howes, O. D. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0135 · Cited by 330 · cited 2×
“Furthermore, as different non-prescribed substances vary in impact on the striatal dopamine system (Ashok et al., 2017; Kamp et al., 2019), comparing individuals without characterizing the type and severity of consequences of the substance(s) used may increase heterogeneity in observational studies.”
BackgroundAntipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
Taipale, H., Mittendorfer-Rutz, E., Alexanderson, K., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.12.010 · Cited by 262 · cited 1×
“Antipsychotic medications are the mainstay of treatment for schizophrenia and are associated with a reduction in psychiatric hospitalization (Tiihonen et al., 2017) and overall mortality (Taipale et al., 2018).”
BackgroundWeiner, D. M., Meltzer, H. Y., Veinbergs, I., Donohue, E. M., Spalding, T. A., Smith, T. T., Mohell, N., Harvey, S. C., Lameh, J., Nash, N., et al. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1940-5 · Cited by 253 · cited 1×
“…(GABA-B)-mediated inhibitory neurotransmission (Nair et al., 2020), N-desmethylclozapine’s muscarinic acetylcholine receptor M1 agonist activity (Weiner et al., 2004), and clozapine’s potent blockade of alpha-2 noradrenergic receptors coupled with an increase in norepinephrine levels (Green…”
Background
Research works printed but not linked: 1
- Brunette MF Dawson R O’Keefe CD, et al. (2011) Clozapine vs. other antipsychotics for schizophrenia and co-occurring cannabis use disorder. Schizophr Bull 37: 297.
Cited by
Bahji, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040999 · Cited by 83
Self-citationAgid, O., Crespo‐Facorro, B., de Bartolomeis, A., Fagiolini, A. M., Howes, O. D., Seppälä, N., & Correll, C. U. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.04.012 · Cited by 47
de León, J., Baldessarini, R. J., Balon, R., Bilbily, J., Caroff, S. N., Citrome, L., Correll, C. U., Cotes, R. O., Davis, J. M., DeLisi, L. E., et al. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001990 · Cited by 39
Management of schizophrenia and comorbid substance use disorders: expert review and guidance
Neyra, A., Parro-Torres, C., Ros‐Cucurull, E., Machado, I. C., Echarri, E., & Torrens, M. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00529-7 · Cited by 39
“…systematic review and meta-analysis has suggested an association between clozapine treatment and significantly more abstinence from (time without consume of) substance use and lower rates of psychiatric hospitalization, compared with other first-and second-generation antipsychotic medications [55].”
ResultChiappini, S., Cavallotto, C., Mosca, A., Carlo, F. D., Piro, T., Giovannetti, G., Pasino, A., Vicinelli, M. C., Lorenzini, C., Paolo, M. D., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17040535 · Cited by 34
“Specifically, according to recent studies, clozapine treat-ment is linked to markedly higher chances of maintaining abstinence from substance use and a reduced probability of psychiatric hospitalization in comparison to continued treat-ment with other antipsychotic medications [27,28].”
BackgroundWhy Is Clozapine Uniquely Effective in Treatment-Resistant Schizophrenia? A Review and Proposal
Murray, R. M., Egerton, A., Gao, Y., Grace, A. A., Howes, O. D., Jauhar, S., Leucht, S., Chen, E. Y. H., MacCabe, J. H., McCutcheon, R. A., et al. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.06.011 · Cited by 35
Suetani, S., Dark, F. L., Every‐Palmer, S., Galletly, C. A., O'Donoghue, B. N., Halstead, S., Keating, D., Korman, N., Lappin, J., Lawn, S., et al. (2026) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251406058 · Cited by 25
Cavallotto, C., Chiappini, S., Mosca, A., d’Andrea, G., Carlo, F. D., Piro, T., Susini, O., Stefanelli, G., Cesare, A. D., Ricci, V., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082206 · Cited by 23
Grunze, H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2266359 · Cited by 19
“A recent review suggested the efficacy of clozapine in schizophrenic patients with alcohol use disorder [90].”
BackgroundRethinking Clozapine: Lights and Shadows of a Revolutionary Drug
Dell’Osso, L., Bonelli, C., Nardi, B., Giovannoni, F., Pronestì, C., Cremone, I. M., Amatori, G., Pini, S., & Carpita, B. (2024) · Brain Sciences · doi:10.3390/brainsci14010103 · Cited by 21
“Current studies supporting this indication are mostly non-randomized [36,44,45,101].”
BackgroundResultDenissoff, A., Taipale, H. T., Tiihonen, J., Forti, M. D., Mittendorfer‐Rutz, E., Tanskanen, A. J., Mustonen, A., & Niemelä, S. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae034 · Cited by 13
Rafizadeh, R., Frankow, L., Mahmood, H., Poonia, S., Mathew, N., Danilewitz, M., Bousman, C., Honer, W. G., & Schütz, C. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231191781 · Cited by 11
“Moreover, some preliminary evidence in SSD-SUD population suggests combination of clozapine, and an LAI antipsychotic may be associated with decrease in risk of ED visits and hospitalization in outpatient community settings (Grimminck et al., 2020) Regarding the impact of additional factors on the MAUD outcomes, both…”
ResultSelf-citationSinclair, J., Kalk, N. J., Kaar, S. J., Agabio, R., Arunogiri, S., Bisaga, A. M., Chesney, E., Daly, C., Dewhurst, J., Freeman, T. P., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251399593 · Cited by 16
Miedlich, S. U., & Lamberti, J. S. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15301 · Cited by 13
Mustonen, A., Taipale, H. T., Denissoff, A., Ellilä, V., Forti, M. D., Tanskanen, A. J., Mittendorfer‐Rutz, E., Tiihonen, J., & Niemelä, S. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.72 · Cited by 8
“38 Cannabis use also associates with treatment resistance in schizophrenia 10 where use of clozapine is indicated.”
Clozapine Prescripers—Dogmatic or Pragmatic?
Naguy, A., & Alhazeem, H. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4490 · Cited by 5
Maremmani, A. G. I., Rocca, F. D., Bacciardi, S., Carbone, M. G., & Maremmani, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155596 · Cited by 4
“These findings remained significant even when evaluating any type of substance use relapse [50,51].”
The Problem of "Dual Diagnosis" in Psychiatry and an Attempt to Solve it
Skugarevsky, O. (2023) · Психиатрия психотерапия и клиническая психология · doi:10.34883/pi.2023.14.3.006 · Cited by 3
Shangraw, K., Schmutz, C., Dowdle, T., Kelley, R., Porter, C., Reynolds, M., Schwartz, Z. T., Sutton, O., & Kious, B. M. (2024) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20240056 · Cited by 3
“There is also some evidence for clozapine in reducing aggressive behavior (29, 30) and potential benefits in patients with comorbid substance use disorders (31, 32).”
Vieta, E., Montejo, Á., Pillinger, T., Dell’Osso, B. M., Dimitraka, M., Farooq, S., Jesús, G., Parro-Torres, C., Wobrock, T., & Pappa, S. (2025) · Annals of General Psychiatry · doi:10.1186/s12991-025-00620-7 · Cited by 2
“Clozapine remains the most effective treatment for refractory schizophrenia [125] and may also benefit patients with persistent comorbid substance use [117, 126].”
Beyond Kraepelin: An Aetiological Approach to the Typology and Treatment of Psychosis
Murray, R. M., Alameda, L., Dima, A., & Oliver, D. (2026) · Springer eBooks · doi:10.1007/978-3-032-09475-9_25 · Cited by 3
de León, J. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002218 · Cited by 2
Vita, A., Barlati, S., Porcellana, M., Sala, E., Lisoni, J., Brogonzoli, L., Percudani, M., & Iardino, R. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1382326 · Cited by 4
“…hand, meta-analytic evidence suggested that clozapine was superior to other AP in reducing substance misuse (81), while other fi ndings observed that clozapine is strongly associated with reduced risk of developing substance use disorders among PLWS (82) maintaining them abstinent from misuse (83).”
BackgroundMills, J., & Long, A. C. (2025) · Issues in Mental Health Nursing · doi:10.1080/01612840.2025.2503132 · Cited by 1
“Yet another meta-analysis found clozapine to be associated with significantly higher rates of recovery in substance use disorders and decreased chances of psychiatric hospitalization (Rafizadeh et al., 2023).”
Frankow, L., Bousman, C., Mathew, N., & Rafizadeh, R. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251408172 · Cited by 1
Self-citationMosca, A., Cavallotto, C., Chiappini, S., d’Andrea, G., Carlo, F. D., Marrangone, C., Allegretti, R., Ciraselli, N., Pepe, M., Dattoli, L., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19030423 · Cited by 2
The role of 5-HT3 receptors in schizophrenia and associated depressive and addictive comorbidities
Jůza, R., Więckowska, A., Vojtěchová, I., Kuča, K., Soukup, O., Korábečný, J., & Petrásek, T. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111663 · Cited by 1
Clinical quandaries in psychotic disorders: the road is long, with many a winding turn
Jauhar, S., & McCutcheon, R. A. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231206445 · Cited by 1
Prescription des antipsychotiques
Zante, É., & Franck, N. (2025) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(24)45738-6
Burger, T. J., de Haas, H. J., Eck, R. M. V., Kikkert, M., Schirmbeck, F. N., Vellinga, A., de Haan, L., & de Koning, M. B. (2025) · International Journal of Social Psychiatry · doi:10.1177/00207640251358418
“Clozapine has unique efficacy in treatment-resist-ant schizophrenia (Kane et al., 1988; Tiihonen et al., 2017), and schizophrenia related substance use, suicidality, and aggression, which are often part of complex psychosis (Correll et al., 2022; Faden & Citrome, 2024; Rafizadeh et al., 2023).”
Yousuf, S. M., Eldous, A. Z. K., Ikhlef, F. W., Chandrappa, N. S. K., & Alabdulla, M. (2025) · Case Reports in Psychiatry · doi:10.1155/crps/9578923
“Its ef fi cacy extends beyond psychosis management to ameliorate frequently co-occurring symptoms such as anxiety, insomnia, and affective instability, which often complicate SUD treatment and recovery [10 – 12].”
Clozapine for Optimal Schizophrenia Care: A Mission-Critical Medication
Lim, C., & Freudenreich, O. (2025) · Korean Journal of Schizophrenia Research · doi:10.16946/kjsr.2025.28.2.29
“In addition, those with comorbid substance use disorders, 29) catatonic features, or sensitivity to extrapyramidal symptoms, including established tardive dyskinesia, should also be considered good candidates for early clozapine intervention.”
Addiction is a mental disorder within the mental health spectrum, and it matters
Schütz, C. G., Thiessen, K. A., Lam, A., Song, M. J., & Todesco, S. (2025) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2025.10157 · Cited by 1
Self-citationMiller, C. O. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-13315-1_5
Grover, S. (2025) · Journal of Mental Health and Human Behaviour · doi:10.4103/jmhhb.jmhhb_245_25
Urrego-Novoa, J. R., Leguizamón, K. A. M., Parra, K. Q., Granados, U. C., Cadena, D. D., Higuera-Dagovett, E., Valencia, J. T. R., & Galeano, J. T. (2026) · Revista Colombiana de Ciencias Químico Farmacéuticas · doi:10.15446/rcciquifa.v55n1.125020
Proportion and Reasons for Clozapine Discontinuation: A Systematic Review and Meta-Analysis
McLaughlin, P., McManus, R., Conaty, O., Al-Harbi, F., Gaughran, F., O'Donoghue, B. N., & Lally, J. (2026) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgag016 · Cited by 1
Dmitrieva, S. O., & Kostyuk, G. P. (2026) · Psikhiatriya · doi:10.30629/2618-6667-2026-24-2-90-99
Rafizadeh, R., Frankow, L., Seethapathy, V., Hestvik, L., Tanyous, M., Mathew, N., Schütz, C. G., & Bousman, C. (2026) · The Canadian Journal of Psychiatry · doi:10.1177/07067437261486956
Self-citationLost in translation: why don't dopamine D2 antagonists cure addictions?
Leyton, M., & Palaniyappan, L. K. (2026) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn-2026-0097
Teixeira, A. L. S., de Oliveira, L., Sorato, G. B., Manjabosco, F. D. M., Bezerra, O. S., & Graeff‐Martins, A. S. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6040057
Metadata
- Authors
- Rafizadeh, R., Danilewitz, M., Bousman, C. A., Mathew, N., White, R. F., Bahji, A., Honer, W. G., & Schütz, C. G.
- Affiliations
- University of British Columbia (CA)
- University of Toronto (CA)
- University of Calgary (CA)
- Corresponding author
- Rafizadeh, Reza
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-12-12
- Volume
- 37
- Issue
- 2
- Pages
- 135-143
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC9912304
- OpenAlex
- W4311204828
- Cited by
- 41
- References
- 55
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 9 · 2023: 4
- FWCI
- 1.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (R25DA037756)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- clozapine, substance use disorders, schizophrenia spectrum disorders, alcoholism, abstinence, psychiatric hospitalization, antipsychotic drugs, comorbidities, treatment-resistant psychosis
- MeSH terms
- Clozapine, Female, Humans, Male, Nicotine, Schizophrenia, Antipsychotic Agents, Substance-Related Disorders, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

